http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013137960-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 2012-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013137960-A |
| titleOfInvention | INHIBITORS FOSFOGIDROLAZ phosphatidic acid (PAP), INCLUDING D-PROPRANALOL and analogues, alone or in combination With desipramine FOR THE TREATMENT OF CANCER TYPES WHICH VARY FROM epidermal growth factor (the FGFR), ITS oncogenic variants and other members of the receptor tyrosine kinase ErbB / HER |
| abstract | 1. The use of an inhibitor of the enzyme phosphohydrolase phosphatidic acid (PAP) or a combination of inhibitors, the inhibitor being D (+) propranolol, and the combination contains a racemic mixture of propranolol or the enantiomer D (+) propranolol with desipramine to prepare a medicament useful for treating cancer and the cancer is dependent on the epidermal growth factor receptor (EGFR), its oncogenic variants (EGFR mutants) or other members of the ErbB / HER.2 family. The use of claim 1, wherein the combination contains a racemic mixture of propranolol with desipramine. 3. The use of claim 1, wherein the combination contains D (+) propranolol with desipramine. 4. The use according to claim 1, wherein the epidermal growth factor receptor-dependent (EGFR) and ErbB / HER-dependent cancers are selected from cancer of the lung, breast, colorectal cancer, cancer of the head and neck, pancreas, ovaries, stomach and esophagus, liver , prostate, melanoma and / or glioblastoma. 5. The use according to claim 1, wherein the combination of PAP inhibitors is used alone or in combination with other drugs that inhibit EGFR, its oncogenic variants (EGFR mutants) or other members of the ErbB / HER family via a pathway other than PAP inhibition. The use of claim 1, wherein the PAP inhibitors are used alone or in combination with other methods, such as radiation therapy or surgery. |
| priorityDate | 2011-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.